Mark Rus, MSc
Mark Rus serves as President & Chief Executive Officer of Delix. He brings a range of leadership experience and impact across small to large pharma, venture capital, and biotech start-ups. Prior to helping build the Delix team, strategic plan, fundraising, and related company-building efforts, Mark served as an Entrepreneur-in-Residence and Venture Advisor at Atlas Venture, where he focused primarily on novel preclinical neuropsychiatric assets. Mark also spent over 13 years at Shire as the Group Vice President (Neuroscience) and a range of other senior commercial, strategic, and operational positions, until the sale of the company to Takeda. In that time, he lived and led teams across the United States, Europe, Canada, and Japan, at multiple clinical and commercial stages. His teams were responsible for several in-market and PI-III pipeline assets, ultimately building a growing $2.5BN neuroscience business across 5 continents.
Mark holds a MSc degree in Political Economics from the London School of Economics and a BA (Hons.) in Political Science & International Comparative Studies from Huron University. He also has a professional background in Canadian Federal Politics, and served for several years as a policy advisor and political aide in Canada’s Privy Council Office, on the Minister of State’s staff, and Prime Minister of Canada’s election team. He was nominated by Pharmaceutical Executive Magazine in 2017 as one of the top 11 Emerging Leaders in the life sciences, serves on the Board of Directors of the Waltham Boys & Girls Club, and several other local non-profits and Boards.